Sequantrix Launches Operations
Sequantrix identifies and validates novel, antifibrotic targets by leveraging one of the world’s largest human…
Sequantrix identifies and validates novel, antifibrotic targets by leveraging one of the world’s largest human…
Has served in interim role since January 2023 HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE)…
Has served in interim role since January 2023 HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE)…
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patients MUNICH,…
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patients MUNICH,…
– Using ProMagen™ in combination with standard chemicals or other biological solutions demonstrated more efficient…
– Using ProMagen™ in combination with standard chemicals or other biological solutions demonstrated more efficient…
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals…
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals…
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corp. (NASDAQ: PDSB), a…
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corp. (NASDAQ: PDSB), a…
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation…
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation…
Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary…
Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary…
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider…
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider…
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT)…
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT)…
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy…